Eli Lilly and Co (NYSE:LLY) released underwhelming data from a Phase 3 ATTAIN-1 trial evaluating orforglipron, an investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist.
For the primary endpoint, orforglipron 36 mg lowered weight by an average of 12.4% (27.3 lbs) compared to 0.9% (2.2 lbs) with placebo using the efficacy estimand, below Wall Street’s expectations of around 15%.
